跨美迪克斯医疗

最新新闻

• GUIDANCE: (TMDX) TransMedics Expects Full Year 2026 Revenue Range $737M - $757M, Vs. FactSet Est of $743.1M
  MT Newswires · 2026/9/11
• 评级变动
  CCORF Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $124
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• Needham Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $106
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Aquestive Therapeutics (AQST) and Alto Neuroscience, Inc. (ANRO)
  TipRanks · 2026/6/26
• 评级变动
  Needham Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $106
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 评级变动
  A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $95 to $106
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• 评级变动
  Evercore Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $90
  \u5e02\u573a\u8d44\u8baf · 2026/7/6
• 评级变动
  A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $95 to $122
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  Stifel Maintains TransMedics(TMDX.US) With Hold Rating, Maintains Target Price $80
  \u5e02\u573a\u8d44\u8baf · 2026/6/26
• 评级变动
  Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $120
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $120
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  TransMedics (TMDX): Buy Rating Backed by Accelerating U.S. Organ Transplant Volumes and Expanding OCS Utilization
  TipRanks · 2026/8/3
• William Blair Maintains TransMedics(TMDX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $100
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Raises Target Price to $100
  \u5e02\u573a\u8d44\u8baf · 2026/9/12
• 评级变动
  CCORF Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $95
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Oppenheimer Maintains TransMedics(TMDX.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/24
• 评级变动
  Stifel Maintains TransMedics(TMDX.US) With Hold Rating, Raises Target Price to $80
  \u5e02\u573a\u8d44\u8baf · 2026/6/18
• 评级变动
  Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $120
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $90
  \u5e02\u573a\u8d44\u8baf · 2026/9/2

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。